New therapies for treatment of HER2 tumors

Studies presented at ASCO seek new therapies to treat HER-2 Positive tumors. This type of tumor is associated with HER-2 protein that promotes the growth of cells, in the case of breast cancer, of mammary cells.

Memorial Sloan Kettering Cancer Center

Bob T. Li, MD, MPH, of Memorial Sloan Kettering Cancer Center, discussed the results of the recently approved drug, adotrastuzumab emtansine, in a multicenter study involving patients with HER2-amplified or HER2-mutated cancers.

According to Dr. Li, "adotrastuzumab emtansine has demonstrated clinical efficacy against lung cancer amplified, endometrial glands, salivary glands and other cancers amplified with HER2."

It was observed that the degree of HER2 amplification is correlated with the response to treatment, but not all HER2-amplified cancers responded in the same way.

MD Anderson Cancer Center

Another study focusing on new drugs for HER2 tumors was also presented. Funda Meric-Bernstam, MD, of the University of Texas, MD Anderson Cancer Center, presented an analysis on the ZW25 agent, an antibody to HER2.

This study was divided into two parts. The first to set the optimal dosage for the treatment. The second, which is still in progress, seeks to define the effectiveness and safety of the use of this agent.

Aichi Cancer Center

Dr Hiroji Iwata of Aichi Cancer Center, Japan, presented data on the long-term efficacy and safety of trastuzumabe deruxtecan, a drug / antibody conjugate that aims to treat HER2 tumors.

Esse tratamento está em testes e, segundo os pesquisadores, tem demonstrado uma atividade de combate ao tumor de uma forma promissora, em pacientes de câncer de mama e gástrico que passaram por outros tratamentos para HER2 Positivo. 

Source: ASCO